 |
|
|
|
|
|||||||||||||||
 |
|||||||||||||||||||
|
|
|
|
|
|||||||||||||||
|
|||||||||||||||||||
| ;
treatment of ulcerative proctitis and colitis colitis foundation of america crohn's-and colitis foundation of america dealing with ulcerative colitis treatment of colitis ulcerosa compositions and method -fo -treatment of ulcerative colitis detection and treatment of ulcerative colitis method of treating ulcerative colitis method of treating ulcerative colitis with a monoclonal antibody methods for the treatment of ulcerative colitis methods of treating established colitis using antibodies therapeutic agent for ulcerative colitis therapeutic-and-diagnostic-methods for ulcerative colitis and associated disorders treating a patient with ulcerative colitis methods of treatment for ulcerative colitis using aminosalicylate therapeutic agent for ulcerative colitis therapeutic-and-diagnostic-methods for ulcerative colitis and associated disorders treating a patient with ulcerative colitis .
fish oils benefit patients with ulcerative colitis crohn's disease and ulcerative colitis !!!!
|
The present invention relates to a drug for treating a patient with ulcerative colitis, which is one of the intractable diseases of unknown origin, a method for screening such a drug, a method for treating a patient with the disease, a prophylactic drug, a method for preventing such a disease, a vaccine for the disease, a diagnostic drug, a diagnostic method, an experimental model for the disease and an experimental animal for the disease. Ulcerative colitis is one of the intractable diseases of digestive tracts and a unknown etiology. It has conventionally been regarded as an advantageous opinion that the ulcerative colitis would be a kind of autoimmune disease. For this reason, there have been used, for instance, steroid hormones, salazosulfapyridine and 5-ASA having an anti-inflammatory action. The administration of these drugs may clinically improve the symptoms of patients with this disease, but the disease recurs in most of cases, on a long term follow-up. Moreover, inflammatory findings still remain in both endoscopic and pathological findings in most of the cases of the disease, although the symptoms are improved. In other words, there has not yet been any drug for completely curing the disease. Fusobacterium varium is a bacterium belonging to the genus Fusobacterium of the family Bacteroidaceae and was detected from the mucosa of a patient with ulcerative colitis at the active phase by bacterial cell culture and immunostaining. The rates of these detections were significantly higher than those observed for patients with ulcerative colitis at the remission stage, Crohn's disease, ischemic colitis, and colomic adenoma. Therefore, this bacterium is considered to be a causal bacterium or an exacerbation factor. From such information, it would be concluded that the patients with ulcerative colitis could be cured by administering a drug selectively killing this bacterium or an antimicrobial agent to remove the bacterial cells from the mucosa in the lesions. More specifically, there can be used antimicrobial agents having high susceptibility to Fusobacterium varium, such as tetracycline, penicillin, MNZ, imipenem, amoxicillin, cefmetazole, ampicillin, fosfomycin and chloramphenicol. It has been recognized that the toxins produced by Fusobacterium varium cells have toxicity to vero cells. Therefore, the toxins were analyzed and it was found that they were organic acids produced by Fusobacterium varium and that the principal component thereof was identified to be butyric acid. Thus, when butyric acid was injected into the rectum of a mouse, a lesion similar to ulcerative colitis was induced. Accordingly, if administering a drug, which can neutralize and/or adsorb the butyric acid to a patient, the development of any lesion may be prevented or such conditions may be treated. Specifically, an agent for adsorbing organic acids such as activated carbon can be employed. Since Fusobacterium varium cells are adhered to the surface mucosa of active ulcerative colitis, the crisis of ulcerative colitis can be prevented by inhibiting the adhesion of Fusobacterium varium cells to the affected mucosa even if Fusobacterium varium cells are present in the intestinal flora. Specifically, a drug for protecting mucosa such as sucralfate and ecabe sodium can be used. As an evidence that Fusobacterium varium cells invade from digestive tracts into the intestinal mucosa, an antibody (serum antibody) against Fusobacterium varium is detected in the sera of the patients with ulcerative colitis in a high detection rate and high antibody titers by the ELISA assay. There has recently been elucidated the invasion mechanism of various kinds of bacteria into mucosa. Bacteria act on the mucosal cells by themselves to thus make the cells produce receptors and then they invade into the cells. Fusobacterium varium cells may possess the same function. Moreover, it would be considered that if Fusobacterium varium cells invade into the mucosa, macrophages can be activated and they may be involved in the crisis and exacerbation of inflammation. Therefore, the inflammation can be controlled by blocking the process of the bacterial invasion into the mucosa. If a vaccine against Fusobacterium varium is developed, it would be possible to immediately eliminate Fusobacterium varium cells even if infected therewith and to prevent any crisis of ulcerative colitis or to inhibit the exacerbation of the symptoms, as in the case where the infection with pneumococcus can be inhibited by the vaccination with a pneumococcal vaccine. A target drug can be screened by establishing an experimental infection model using a sterilized animal or a small animal in which Fusobacterium varium cells are adhered to the colonic mucosa. In these animals, a candidate drug administered to the experimental animal, can be evaluated whether the candidate drug can selectively kill Fusobacterium varium cells or not, by the culture, immunostaining and the serum antibody titer. Patients with ulcerative colitis infected with Fusobacterium varium with are identified by diagnosing patients suffering from ulcerative colitis through the determination of the serum antibody titers, the cultivation of the mucosa or the immunostaining of affected mucosa, and then a candidate drug capable of selectively killing Fusobacterium varium is administered to the patients after obtaining the informed consent of patients. Thus, the effectiveness of the drug as a therapeutic agent for ulcerative colitis can be evaluated by the symptoms of the ulcerative colitis are, in fact, improved or not and by investigating the presence of side effects and safety of the drug. Moreover, the principal component of the toxin against the vero cells produced by Fusobacterium varium is found to be butyric acid, and butyric acid is injected into the colon of a small animal such as a mouse or a rat to thus establish a lesion similar to ulcerative colitis. Fusobacterium varium cells are inoculated to germ-free
animal or an compromised small animal and adhere the bacterial cells to
the colonic mucosa. Moreover, it is also possible to find out animals highly
sensitive to the adhesion of living bacterial cells to the intestinal mucosa
by the inoculation of Fusobacterium varium cells into a variety of animals.
Thus, an ulcerative colitis-like lesion can be developed or established
in these animals and the establishment of such a lesion in the animals
or the infection thereof with Fusobacterium varium can be judged on the
basis of the results of the detection of the serum antibody, the immunostaining
of mucosa and culture of the mucosa. If the antibodies are identified by
a method such as the western blot technique and/or an ELISA technique,
a differential diagnosis as ulcerative colitis can be easily made as to
the cases of inflammatory bowel disease, if the diagnosis is difficult.
There are also herbal medicines which can very effectively treat colitis & ulcerative colitis. Boswellia is an Ayurvedic (Indian traditional medicine) herb, used as a natural alternative to drugs. One study has found its effectiveness similar to sulfasalazine. (Source Wikipedia: http://en.wikipedia.org/wiki/Ulcerative_colitis ). We recommend taking a
4 months course of our Boswellia Serrata Extract.
Order Boswellia - Shallaki - 4 Months course
Total
of 4 bottles- of Boswellia
- 4 Months course - Taken 2 capusles twice a day.
(All Inclusive) FREE Shipping Worldwide. There are NO ADDITIONAL
CHARGES. Packing & Shipping is absolutely FREE. We will deliver direct
to your door to reach within 12 days from the date of ordering. A signature
will be required at the time of delivery. You can give us your daytime
work address or Post Box address if no one will be present at home to receive
the shipment during daytime.
Please use the form below to mail us for any information. We will revert back within 10 hours .
|
